| __timestamp | Amneal Pharmaceuticals, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 106735000 | 7459000 |
| Thursday, January 1, 2015 | 136870000 | 11831000 |
| Friday, January 1, 2016 | 204747000 | 25705000 |
| Sunday, January 1, 2017 | 191938000 | 46181000 |
| Monday, January 1, 2018 | 210451000 | 59497000 |
| Tuesday, January 1, 2019 | 202287000 | 65003000 |
| Wednesday, January 1, 2020 | 190585000 | 74506000 |
| Friday, January 1, 2021 | 209563000 | 126006000 |
| Saturday, January 1, 2022 | 200046000 | 126215000 |
| Sunday, January 1, 2023 | 167778000 | 120161000 |
Igniting the spark of knowledge
In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Amneal Pharmaceuticals and Protagonist Therapeutics have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Amneal Pharmaceuticals consistently allocated a significant portion of its resources to R&D, peaking in 2018 with a 97% increase from 2014 levels. However, a notable decline of 20% was observed in 2023, reflecting potential strategic shifts or market challenges.
Conversely, Protagonist Therapeutics exhibited a remarkable upward trajectory, with R&D spending surging by over 1,500% from 2014 to 2023. This aggressive investment strategy underscores Protagonist's focus on pioneering therapeutic solutions. The data reveals a compelling narrative of how these two companies prioritize innovation, with Protagonist's R&D spending catching up to Amneal's by 2021, highlighting a dynamic shift in the pharmaceutical R&D landscape.
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Amneal Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for BeiGene, Ltd. and Amneal Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for BeiGene, Ltd. and Protagonist Therapeutics, Inc.
Research and Development Investment: Halozyme Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
R&D Insights: How Lantheus Holdings, Inc. and Protagonist Therapeutics, Inc. Allocate Funds
Ionis Pharmaceuticals, Inc. vs Amneal Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Amneal Pharmaceuticals, Inc. vs Rhythm Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Amneal Pharmaceuticals, Inc. vs CRISPR Therapeutics AG: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Amneal Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Analyzing R&D Budgets: Xenon Pharmaceuticals Inc. vs Protagonist Therapeutics, Inc.
R&D Spending Showdown: Vericel Corporation vs Protagonist Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for HUTCHMED (China) Limited and Protagonist Therapeutics, Inc.